Unilateral blepharoptosis secondary to the intramuscular injection of botulinum toxin

Abstract

Botulinum toxin type A is widely used to reduce the dynamic rhytides associated with repetitive use of the underlying muscles in the upper third of the face. However, as its use has grown, appreciation of the risk of complications and their management may be underestimated. This case report of a 33-year-old female patient presenting with eyelid ptosis, or unilateral myogenic blepharoptosis, revisits the management of a complication associated with the use of botulinum toxin type A for facial rejuvenation. The patient reported difficulty in attaining maximal aperture of the left eye 3 days post treatment. This was successfully managed using 0.5% apraclonidine instilled three times daily for 6 weeks.